Microbiome-Targeted Antibiotics Provide No Additional Microbiologic or Inflammatory Benefit during Cystic Fibrosis Pulmonary Exacerbations: Results from the CFMATTERS Trial. - Einarsson GG; Lee AJ; Alfahl Z; Kerrigan L; Eustace JA; Weldon S; Plant BJ; Elborn JS; Taggart CC; Mall MA; Tunney MM (American journal of respiratory and critical care medicine, 2026)